Financials:

  • Bad debt is written off worth 17crs 
  • India business: Leading company in Macrolides (a segment of anti-infectives) as well as other acute therapies.
    • Made a mark in some specialized therapies such as Diabetology, Cardiology, and Gynaecology as well. (chronic & sub-chronic therapies)
    • A high specialty Ophthalmic range has been introduced in the Ophthalcare Division in the domestic market. (See if they are able to scale up)
  • US Business: Received 15 ANDAs approval.
    • Strategy in International Generics is to partner with International Generic companies and leverage their marketing and sales capabilities. 
    • It shares the investment and returns with the marketing partners and this helps de-risk its ANDA program and reduces the upfront investment in the development stage. (Capital light approach)
    • Timely and accelerated quality filling ANDAs / DMF will be a key focus area.
  • The company has 300 scientists working across two development centers.